ALBUQUERQUE, N.M. - (Business Wire) The New Mexico Biotechnology & Biomedical Association (
NMBio) elected the 2008 Board of Directors at the February Annual Meeting. The Board of Directors works with NMBio to provide a forum for information exchange related to life science activities, develop initiatives to enhance small business success, provide education regarding the NM biosciences, help establish collaborations, and publicize the bioscience industry.
The 2008 Board of Directors are:
- Robert Curtis, Robert Curtis Associates
- Terry Dunlay, President and CEO, IntelliCyt Corporation
- Woody Ediger, CTO, VeraLight
- Marion Karvas, Business Development Manager, Lovelace Scientific Resources
- Louis J. Lafrado, Ph.D., L&D Associates
- Richard S. Larson, Ph.D., M.D. Vice President for Translational Research, University of New Mexico Health Sciences Center
- Jerome A. Mattingly, Ph.D., President, New Mexico Angels
- Jose Olivares, Ph.D., Deputy Division Leader, Bioscience Division – Los Alamos National Laboratory
- Jens Poschet, Ph.D., Staff Scientist, Sandia National Laboratories
- Leah Pulling, Ph.D., Director of Biotechnology Program, Central New Mexico Community College
- Peter Rachor, Desert Oasis LLC
- Andrew Salazar, Director, Project Development Technology Ventures Corporation
- Shannon Sheehan, Ph.D., Director Life Sciences, Science & Technology Corporation at UNM
- Katie Szczepaniak Rice, Analyst Wasatch Venture Fund
- Janeen Vilven-Doggett, Ph.D., J.D., Attorney, Peacock Myers, P.C.
- Gilberto Zamora, Chief Technology Officer, Orion International Technologies
Robert Curtis
Bob Curtis served as an NMBio board member in 2006-2007 and is currently serving as Treasurer. Bob has over seven years of venture capital experience, along with 25 years of medical technology company operating experience, including 17 years at the CEO/GM level at the following: MedTech Ventures, Inc. / VanMed V, Inc.; CardioPulmonics, Inc. (NASDAQ: CRDS), Urosystems, Inc. (acquired by Medtronic Inc.), Autogenics, Inc., and Aerogen, Inc. (NASDAQ: AEGN) and five other startup medical technology companies; and Shiley, Inc. (“Shiley”), a $200+ million cardiovascular medical device subsidiary of Pfizer, Inc. Bob holds a B.S. in Chemical Engineering and an M.S. in Mechanical/Bioengineering from the University of California, Berkeley. He has served on the board of multiple private and public companies. He is the inventor of multiple successful medical device products, holds 11 U.S. and foreign patents, and has patents currently pending. During his career he has raised and invested over $165 million in corporate and venture capital.
Terry Dunlay
Terry Dunlay is the President and CEO of IntelliCyt Corporation, a life science technology company located in Albuquerque, N.M. He has over 25 years of experience in technology development and commercialization, including the last 18 years in entrepreneurial life science ventures. Prior to IntelliCyt, he co-founded Cellomics, Inc., in Pittsburgh, Pa., a life science tools company that was acquired by Thermo Fisher, where he held senior management positions, including Executive Vice President. He invented and commercialized Cellomics' High Content Screening instrumentation and informatics software products to enable researchers at biotechnology firms, pharmaceutical companies, and academic institutions to analyze cells and cell-function quickly, including the way potential drugs interact with cells. Prior to Cellomics, he co-founded and was President and CEO of Biological Detection, Inc., an imaging software company that served the biomedical research market. Prior to BDI, he held various engineering management positions, including Vice President of Engineering, at Biological Detection Systems, Inc., where he led development of microscope-based imaging systems and imaging software products for the biomedical research market. Terry has a M.S. and B.S. Electrical Engineering. He holds 14 issued patents.
Woody Ediger
Marwood “Woody” Ediger is a specialist in fluorescence spectroscopy and tissue optics. He has studied the complex interaction of light and tissue throughout his career. Prior to joining InLight Solutions in 2003, he spent 16 years at the Food and Drug Administration (FDA) as a senior optical scientist in at the Center for Devices and Radiological Health (CDRH). Dr. Ediger received a B.S. in physics from Gustavus Adolphus College and his M.S./Ph.D. in electrical engineering from the University of Illinois. Woody is a member of the NMBBA Board of Directors.
Marion Karvas
Marion is currently Business Development Manager of Lovelace Scientific Resources (LSR) a clinical trials company, representing LSR alongside Lovelace Respiratory Research Institute, the Center for Pharmoeconomic and Outcomes Research and Lovelace Intelligence Systems. Prior to LSR, Marion was in pharmaceutical sales for six years. She has also worked for American International Group (AIG) in New Mexico and Texas. Marion holds a B.S. in Animal Science and Agricultural Communications from Texas Tech University, and holds certification in Training Development and Instructional Technology from UNM Continuing Education. Along with her studies she wrote, photographed and edited an arid lands research newsletter and escorted foreign dignitaries coming to the U.S. through the United State Information Agency to learn about arid lands research.
Louis J. Lafrado, Ph.D.
Louis holds an M.S. in Bacteriology from North Dakota State University, where he worked with the USDA’s Metabolism and Radiation Research Laboratory. Following this degree he worked at the Sloan-Kettering Institute in New York City. From there he went on to The Ohio State University and received his doctorate in veterinary pathology working on feline leukemia virus and feline immunodeficiency virus vaccines and pathology. For several years, Louis was a senior researcher on the Holloman Air Force Base with New Mexico State University, working chimpanzees and AIDS vaccines. In 1994, he accepted a position with the UNM Cancer Research and Treatment Center, and joined the first iteration of NMBBA.
Richard S. Larson, MD, Ph.D.
Dr. Larson is the recipient of the College of American Pathology Lansky Award for his leadership in and contribution to the practice of pathology, UNM Regents Lectureship for contribution to UNM, and American Cancer Society Designated National Investigator for the Coaches against Cancer and Hoops for Lymphoma/Leukemia. Dr. Larson received both his M.D. and Ph.D. from Harvard University. He did his residency training at Washington University at St. Louis, and his fellowship training at Vanderbilt University. Dr. Larson has published over 80 manuscripts involving basic science, clinical and translational research and had a book Bioinformatics and Drug Discovery published by Humana Press in 2005. He was the founder of Cancer Services of New Mexico, and he is chairman of the Board of Directors for TriCore Reference Laboratories, as well as a member of the National Center for Genome Resources Board of Directors.
Jerome A. Mattingly
Jerome A. Mattingly, Ph.D., is currently the President and member of the Board of the New Mexico Angels (NMA), an Angel investment group that invests primarily in New Mexico startup companies. He has been involved operationally with medical devices and medical diagnostics companies for greater than 25 years. He has published over 40 articles in peer-reviewed journals, several book chapters, and he has led the development of several new diagnostic products and medical devices. He has also started up (Founder and CEO) and successfully exited from three separate medical device/diagnostic companies in the Bay Area. Jerry holds a B.S. in Microbiology from the University of Illinois and his Ph.D. in Immunology from the University of Notre Dame. He served a three-year post-doctoral fellowship at Yale University College of Medicine, and was on the faculty of The Ohio State University School of Medicine for five years prior to entering industry.
Jose Olivares
José A. Olivares, Ph.D. is currently Deputy Division Leader for the Bioscience Division at Los Alamos National Laboratory (LANL), which includes ~200 staff and $50 million in programs. He has been at LANL for 20 years. José took a nine month entrepreneurial leave from LANL in 2006 to join Claro Scientific LLC in Tampa, Fla., as Chairman of the Executive Team, VP for R&D and for a short time as CEO. The company was formed to bring to market technologies for bacterial detection primarily developed at the University of South Florida with collaboration and funding from LANL. Prior to his career at LANL, he worked with E.I. Du Pont De Nemours & Co. Savannah River Laboratory; and Battelle Pacific Northwest Laboratories, Richland, Wash., where he designed an interface for capillary zone electrophoresis-mass spectrometry under the direction of research supervisor, Dr. Richard D. Smith. Dr. Olivares received his Ph.D. in Analytical Chemistry, in 1985, from Iowa State University of Science and Technology, Ames, Iowa, and a B.Sc. in Chemistry in 1980 from Wilkes College, Wilkes Barre, Pa. Dr. Olivares has over 33 publications in peer reviewed journals, five patents, and has presented his research work at national and international forums. Jose organized and chaired the Future of Biodetection Systems Workshop, October 2006, Santa Fe, N.M.
Jens Poschet
Dr. Poschet began his career in biological sciences at Ciba-Geigy Pharmaceuticals (now Novartis) in Basel, Switzerland, over 20 years ago. After graduating he worked for Ciba-Geigy on a project that ultimately lead to the introduction of Glivec, the first specific treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Following his work with Ciba-Geigy, Dr. Poschet studied Biochemistry at the University of Manchester, U.K. Upon completion of his B.S., he joined the University of London, St. Bartholomew’s Hospital (U.K.) to study antibiotic transport across small intestinal cells for his Ph.D. Once he finished graduate school, he joined the Royal London Hospital, University of London, studying the effect of proteases on small intestinal infections. In 1999 he joined the University of Michigan, followed by the University of New Mexico, where he study cystic fibrosis. Currently, clinical studies are investigating potential therapeutics on the basis of his work. In 2006, Dr. Poschet joined Sandia National Laboratories, where he is studying host-pathogen interactions, as well as nano-toxicological phenomena. He currently holds an adjunct Research Associate Professorship at the Department of Biology of the University of New Mexico.
Leah Pulling
Director of Biotechnology Program
Central New Mexico Community College
Peter Rachor
Peter Rachor is a business consultant, serving the biotechnology, economic development, media, telecommunications, and other technology industries. Previously, he was Director, Venture Development at Science & Technology Corporation at University of New Mexico, responsible for creating start-up enterprises and joint ventures from technologies developed through research. He also worked with student, faculty and community members to and evaluates new business ventures, through his launch and management of UNM’s Lobo VentureLab, a business accelerator that works with early stage technology companies.
He also worked with Los Alamos Commerce and Development Corporation, assisting inventors and entrepreneurs from Los Alamos National Lab in patent licensing, market assessment, and venture formation.
Mr. Rachor has previously founded three technology ventures himself, and worked with several global telecommunications companies, Lucent Technologies, British Telecom, and Verizon Communications, in the U.S. and internationally.
Peter holds a degree in Finance from Michigan State University, and has completed a certificate in entrepreneurship from Northwestern University's Kellogg School Center for Entrepreneurial Studies. He has been active on the boards of many industry, community service, and leadership organizations, and has also been a guest lecturer in entrepreneurship in several MBA programs. He frequently serves as a mentor, coach or advisor to early stage companies, particularly those being formed by students, university faculty, and scientists.
Andrew Salazar
Mr. Salazar works for Technology Ventures Corporation; he brings a broad range of commercial experience to assist startups in structuring a realistic approach to success. He has held responsibilities in a variety of disciplines including management positions in engineering, manufacturing, finance, sales and economic development. Throughout his career, Mr. Salazar has focused on bringing together the top-flight resources needed for business success. He has a BSME with an EE option from General Motors Institute and a MBA from Stanford University. Andrew is a member of the Board of Directors for the New Mexico Entrepreneurs Association and Hogares, Inc.
Shannon Sheehan
Dr. Sheehan joins the NMBio from the Science and Technology Corporation at UNM where he serves as Director of Life Sciences. Previously he served as Interim Director of Technology Transfer at West Virginia University. He has been working in Technology Transfer for more than 10 years, and is a long-standing member of AUTM, where he serves on two committees. He has facilitated the startup of 15 companies, and has licensed dozens of technologies in both physical and life sciences. Additionally, he has worked as a consultant to Intellectual Property Law firms. He is the author of a book on Technology Transfer and has taught numerous students. Shannon holds a Ph.D. from the University of Illinois School of Chemical Sciences and an MBA from University of Arizona's top-ranked program. Additionally, Dr. Sheehan was a faculty member of the University of Arizona for 11 years, and has first-hand experience moving laboratory inventions to the market.
Katie Szczepaniak Rice
Katie Szczepaniak Rice is an Analyst with Wasatch Venture Fund in Albuquerque, N.M. Wasatch is a venture capital firm headquartered in Salt Lake City specializing in early-stage, information technology and life science investments. Ms. Szczepaniak Rice focuses on new investment opportunities within the IT and biotech sectors as well as the growing alternative energy market, and she actively assists and works with the Wasatch portfolio companies in New Mexico. Katie is currently the chair of the Nano-Network of New Mexico. Prior to joining Wasatch, Katie worked for Cabot Corporation as a Strategic Market Analyst in New Mexico where Cabot develops material technology for alternative energy / fuel cell markets. Before Cabot, she was a consultant with Kline & Co., a business consulting firm in the NYC area that serves Fortune 100 companies, as well as emerging businesses. At Kline, Katie conducted strategy and market analysis consulting engagements focused on biotech, chemicals, materials, nanotechnology, and petrochemical markets. Before Kline, Ms. Szczepaniak Rice was a field engineer with Schlumberger, an oil field service company in France. Katie holds a B.S. in Materials Science & Engineering from the Massachusetts Institute of Technology (MIT). She is currently attending the Executive MBA program at the University of Chicago Graduate School of Business.
Janeen Vilven-Doggett
Janeen Vilven-Doggett is an intellectual property law attorney working with Peacock Myers Law Firm. She is a member of the New Mexico bar and a registered patent attorney. Dr. Vilven-Doggett received her B.A. in Biology from Baylor University in 1986 and her Ph.D. in Biomedical Sciences from the University of New Mexico in 1997. She received her J.D. (cum laude) from the University of New Mexico School of Law in 2001. Prior to becoming an attorney, she spent about 13 years as a research scientist at both Baylor College of Medicine and the University of New Mexico Health Sciences Center. Dr. Vilven-Doggett is a member of the American Intellectual Property Lawyers Association, American Association for the Advancement of Science, and Albuquerque Bar Association. She serves as a volunteer advisor for businesses participating in the Technology Ventures Corporation (TVC) venture capital forum. Dr. Vilven-Doggett is the New Mexico Biotechnology Industry Organization (BIO) state affiliate and also serves on BIO’s intellectual property committee.
Gilberto Zamora
Dr. Zamora is the Chief Technology Officer of Image Processing & Simulation at ORION International Technologies, Inc. He is also in charge of the UMBRA Developing Group. Prior to his work at ORION Gilberto was the Director of Biomedical Imaging at Kestrel Corporation in Albuquerque, N.M. He also directed the development of an Artificial Intelligence System for grading the appearance of skin for one of the world’s largest consumer products companies. Additionally, Gilberto conducted research in diverse aspects of image processing, pattern recognition, and supervised research projects and mentored junior scientists. Gilberto received his doctorate in Electrical Engineering from Texas Tech University in 2002. He received a dual Masters degree in Engineering and Electrical Engineering from Texas Tech University and Fundación Universidad de las Americas-Puebla (Mexico), respectively, in 1998; and a B.S. in Electrical Engineering from Fundación Universidad de las Americas-Puebla in 1995. Dr. Zamora has received honorable mention for his graduate research, and is the author or co-author of more than 15 technical publications and presentations.
About the New Mexico Biotechnology & Biomedical Association
The New Mexico Biotechnology and Biomedical Association (NMBio) works to support and develop the bioscience industry in New Mexico. NMBio strives to provide a forum for information exchange related to life science activities, develop initiatives to enhance small business success, provide education regarding the New Mexico biosciences, help establish collaborations, and publicize the bioscience industry.
For The New Mexico Biotechnology & Biomedical Association
Janeen Vilven-Doggett, 505-998-1500
